Novel inhibitors in the treatment of metastatic melanoma

Expert Review of Anticancer Therapy

Volumn 7, Issue 5, 2007, Pages 715-724

  Kalinsky, Kevin ^a   Haluska, Frank G ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Acral; BAY 43 9006; BRAF; Imatinib; KIT; MAP kinase; Melanoma; Mucosal; PTEN; RAS; Solar elastosis

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTINEOPLASTIC AGENT; AZD 6244; B RAF KINASE; BORTEZOMIB; CARBOPLATIN; CHIR 265; DACARBAZINE; HYDROXYUREA; IMATINIB; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OBLIMERSEN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; PLX 4032; PROTEIN KINASE B; PS 342; RAF PROTEIN; RAS PROTEIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; BRAF PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; BLEEDING; BONE MARROW SUPPRESSION; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERLIPIDEMIA; HYPOTENSION; ILEUS; INFECTION; KIDNEY FAILURE; MELANOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; NEUROPATHY; NEUTROPENIA; NONHUMAN; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SKIN DISEASE; SKIN EXFOLIATION; SKIN MANIFESTATION; STOMATITIS; SUN EXPOSURE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MUTATION; PATHOLOGY; PHYSIOLOGY; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SKIN NEOPLASMS;

EID: 34248524006     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.5.715     Document Type: Review

References (54)

1. American Cancer Society. Cancer Facts and Figures 2006. American Cancer Society Inc. Atlanta, GA, USA 1-21 (2007).
2. Balch C, Buzaid A, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19, 3635-3648 (2001).
3. Gogas H, Kirkwood J, Sondak V, Helen J, Gogas MD. Chemotherapy for metastatic melanoma: time for a change? Cancer 109(3), 455-464 (2007).
4. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
5. Phan G, Attia P, Steinberg S et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 19(15), 3477-3482 (2001).
6. Rosenberg S, Yang J, White D et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 228(3), 307-319 (1998).
7. Goel V, Lazar A, Warneke C, Redston M, Haluska F. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol. 126, 154-160 (2006).
8. Davies H, Bigness GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
9. Pollock PM, Harper UL, Hansen KS et al. High frequency of BRAF mutations in nevi. Nat. Genet. 33, 19-20 (2003).
10. Daniotti M, Oggionni M, Ranzani T et al. BRAF alterations are associated with complex mutational profiles in malignancy melanoma. Oncogene 23, 5968-5977 (2004).
11. Kumar R, Angelini S, Czene K et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin. Cancer Res. 9, 3362-3368 (2003).
12. Houben R, Becker JC, Kappel A et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis (abstract). J. Carcinogenesis 3, 6 (2004).
13. Rodriguez-Viciana P, Marte BM, Warne PH, Downward J. Phosphatidylinositol 3'kinase: one of the effectors of Ras. Philos. Trans. R. Soc. London B Biol. Sci. 351, 225-231; discussion 231-222 (1996).
14. Wu Heng, Goel V, Haluska F. PTEN signaling pathways in melanoma. Oncogene 22, 3113-3122 (2003).
15. Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16, 3397-3402 (1998).
16. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57, 3660-3663 (1997).
17. Goel V, Lazar A, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTFN in primary cutaneous melanoma. J. Invest. Dermatol. 126, 154-160 (2006).
18. Tsao H, Mihm MC, Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi and cutaneous melanoma. J. Am. Acad. Dermatol. 49, 865-872 (2003).
19. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/ protein kinase B in melanoma leads to up-regulation of nuclear Factor-κB and tumor progression. Cancer Res. 62, 7335-7342 (2002).
20. Dai D, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J. Clin. Oncol. 23(7), 1473-1482 (2005).
21. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J. Clin. Invest. 115(4), 813-824 (2005).
22. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 122(2), 337-341 (2004).
23. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
24. Karasarides M, Chiloeches A, Hayward R et al. B-RAF is a therapeutic target in melanoma. Oncogene 23, 6292-6298 (2004).
25. Strumberg D, Voliotis D, Moeller JG et al. Results of Phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int. J. Clin. Pharmacol. Ther. 40, 580-581 (2002).
26. Richly H, Kupsch F, Passage K et al. A Phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int. J. Clin. Pharmacol. Ther. 41, 620-621 (2003).
27. Escudier, B, Eisen T, Staler WM. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
28. Eisen T, Ahmad T, Flaherty KT. Sorafenib in advanced melanoma: a Phase II randomized discontinuation trial analysis. Br. J. Cancer 95(5), 581-586 (2006).
29. Flaherty KT, Lee RJ, Humphries R. Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paclitaxel (P). Proc. Am. Soc. Clin. Oncol. 22, 410 (2003).
30. Lorigan P, Corte P, Chao D et al. Phase II trial investigating safety and preliminary efficacy of sorafenib combined with dacarbazine in metastatic melanoma patients. Presented at: American Society of Clinical Oncology Poster Discussion. June 2-6, Atlanta, GA, USA (2006).
31. Flaherty KT, Lee RJ, Humphries R. Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paclitaxel (P). Proc. Am. Soc. Clin. Oncol. 22, 410 (2003).
32. Solit D, Garraway LA, Pratilas CA. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (7074), 358-362 (2006).
33. Margolin K, Longmate J, Baratta T et al. CCI-779 in metastatic melanoma: a Phase II trial of the California Cancer Consortium. Cancer 104(5), 1045-1048 (2005).
34. Hudes G, Carducci M, Tomczak P et al. A Phase 3, randomized, three-arm study of termsirolimus or interferon-α or the combination of temsirolimus + interferon in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. J. Clin. Oncol. 24(18 Suppl.), LBA4 (2006).
35. Wan X, Harkavy B, Shen N et al. Rapamycin induces feedback activation of AKT signaling through an IGF- 1R-dependent mechanism. Onocogene 26(13), 1932-1940 (2007).
36. King R, Deashaies R, Peters J et al. How proteolysis drives the cell cycle. Science 274, 1652-1659 (1996).
37. Hamilton A, Eder J, Pavlick J et al. Proteasome inhibition with bortezomib (PS-341): a Phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J. Clin. Oncol. 23(25), 6107-6116 (2005).
38. Richardson P, Barlogie B, Berenson J et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617 (2003).
39. Markovic S, Geyer S, Dawkins F et al. A Phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103(12), 2584-2589 (2005).
40. Soengas M, Lowe S. Apoptosis and melanoma chemoresistance. Oncogene 22, 3138-3152 (2003).
41. Bedikian A, Millward M, Pehamberger H et al. Bc1-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. 24(29), 4738-4745 (2006).
42. Leiter U, Schmid R, Kaskel P et al. Antiapoptotic Bcl-2 and Bcl-x1 in advanced malignant melanoma. Arch. Dermatol. Res. 292(5), 225-232 (2000).
43. Zhuang L, Lee C, Scolyer R et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol. 20(4), 416-426 (2007).
44. Krause D, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172-187 (2005).
45. Carroll M, Ohno-Jones S, Tamura S et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood90, 4947-4952 (1997).
46. Curtin J, Busam K, Pinkel D, Bastian B. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24(26), 4340-4346 (2006).
47. Heldin CH, Wetermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79, 1283-1316 (1999).
48. Shen SS, Zhange PF, Eton O, Prieto VG. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J. Cutaneous Pathol. 30, 539-547 (2003).
49. Redondo P. Lloret P, Andreu EJ et al. Imatinib mesylate in cutaneous melanoma. J. Invest. Dermatol. 123(6), 1208-1209 (2004).
50. McGary EC, Onn A, Mills L et al. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J. Invest. Dermatol. 122(2), 400-405 (2004).
51. Grossman D. Imatinib mesylate for melanoma: will a new target be revealed? J. Invest. Dermatol. 123(6), XI-XIII (2004).
52. Curtin J, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147 (2005).
53. Wyman K, Atkins MB, Prieto V et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106(9), 2005-2011 (2006).
54. Eton O, Billings L, Kim K et al. Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma. J. Clin. Oncol. 22(14S), 7528 (2004).